According to a recent LinkedIn post from Hemanext, the company is emphasizing hypoxic storage as a way to reduce unit-to-unit variability in red blood cell (RBC) quality during storage. The post describes how removing oxygen before storage, preserving ATP and 2,3-DPG, and maintaining membrane integrity may help stored blood behave more like freshly donated blood at transfusion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Hemanext ONE® as a system designed to deliver this hypoxic storage approach, positioning it as a tool to support more predictable transfusion performance, particularly for patients requiring multiple units over time. For investors, this focus suggests a strategy aimed at differentiation in transfusion medicine technology, which could strengthen the company’s competitive standing if clinical evidence and adoption by blood banks and hospitals materialize.
By citing multiple peer-reviewed studies, the LinkedIn content appears to target a clinically sophisticated audience and may support credibility with potential partners and clinicians. If Hemanext can translate this technical positioning into regulatory clearances, reimbursement support, and commercial traction, the technology could open a niche in the blood storage and transfusion value chain, with potential for recurring revenue from system use across healthcare settings.